BMO Capital initiated coverage of Rocket Pharmaceuticals (RCKT) with an Outperform rating and $50 price target The gene therapy company has “two major differences from the typical gene therapy ...

GW 170817 marks the first gravitational wave detection of a binary neutron-star (BNS) merger by the Advanced LIGO and the Advanced VIRGO detectors. This is also the first gravitational wave event from ...

Morgan Stanley analyst Sean Laaman assumed coverage of Jazz Pharmaceuticals (JAZZ) with an Overweight rating and a price target of $183, up from $175. The firm model higher oxybate revenue than ...

DUBLIN and DURHAM, N.C., March 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") and Chimerix (Nasdaq: CMRX) ("Chimerix ...

The Company provided the above adjusted supplemental financial performance measures, which are considered "non-GAAP" financial measures under applicable SEC rules and regulations. These financial ...

Since peaking above £37 in 2007 the shares have lost 99.7 per cent of their value. GW Pharmaceuticals rose 33.8 per cent after releasing new trial data on its Sativex cannabis-based mouth spray ...

NASHVILLE, Tenn., Feb. 25, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its annual 2024 financial ...

DUBLIN, Feb. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in TD Cowen's 45 th Annual Health Care Conference. Company management ...

DUBLIN, Feb. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in TD Cowen's 45 th Annual Health Care Conference. Company ...

This breakthrough follows GW Pharmaceuticals' $7.2 billion acquisition, highlighting the potential of cannabis-based epilepsy treatments. Argent BioPharma's CannEpil® is poised to follow a similar ...

GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2019 Financial Results and Operational Progress Total revenue of $109.1 million for the fourth quarter and $311.3 million for the full..